The Traderszone Network

20 March, 2015 by The TZ Newswire Staff Comments Off on Gartman: Crude could hit $15. Here’s why

Gartman: Crude could hit $15. Here’s why

Commodities King Dennis Gartman says a combination of supply issues and a stronger dollar will cause a “stunning” decline for crude prices.

20 March, 2015 by The TZ Newswire Staff Comments Off on Here are the 5 best ideas from the Republican and Democratic budgets

Here are the 5 best ideas from the Republican and Democratic budgets

Washington could actually get something done, if politicians wanted to.

20 March, 2015 by The TZ Newswire Staff Comments Off on Apple’s TV service will likely be much more important than everyone thinks: Henry Blodget

Apple’s TV service will likely be much more important than everyone thinks: Henry Blodget

Is this the end of cable?

20 March, 2015 by The TZ Newswire Staff Comments Off on Washington needs to kick ‘extraordinary measures’ habit: Holtz-Eakin

Washington needs to kick ‘extraordinary measures’ habit: Holtz-Eakin

On Monday, the Treasury Department started taking “extraordinary measures” to keep the government from defaulting on its debt limit, a figure which now exceeds $18 trillion. The Fed’s had extraordinary monetary policy for six years. What is ‘extraordinary’ anymore?

20 March, 2015 by The TZ Newswire Staff Comments Off on Biotech, real estate and Greece: What to watch today

Biotech, real estate and Greece: What to watch today

Yahoo Finance’s Mike Santoli has three things you should keep an eye on while trading today.

20 March, 2015 by The TZ Newswire Staff Comments Off on Cramer: Tiffany’s gotta get off its luxury throne

Cramer: Tiffany’s gotta get off its luxury throne

CNBC’s Jim Cramer says Tiffany’s current business model doesn’t work. Here’s why.

20 March, 2015 by The TZ Newswire Staff Comments Off on Biogen Idec Inc.’s Stock Bursts Higher On Alzheimer’s News: Here’s Why

Biogen Idec Inc.’s Stock Bursts Higher On Alzheimer’s News: Here’s Why

Biogen Idec reported impressive clinical results for its experimental Alzheimer’s disease drug today. Here’s what you need to know.

read more